Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.26
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.26
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.91 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$775.53M
Enterprise ValueAU$1.53K
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)55.6
Beta0.61
Next Earnings
Aug 25, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield3.48%
Share Statistics
EPS (TTM)0.04
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.58
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.07Price Target Upside36.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.14
Revenue Forecast (FY)AU$850.48M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth near 27.7% indicates expanding patient volumes and stronger utilisation of the clinic network. Durable demand for imaging and recurring referral streams support topline momentum and better fixed-cost absorption over the next 2–6 months.
High Gross MarginAn extraordinarily high gross margin reflects efficient delivery of imaging services and pricing power across modalities. With high contribution margins, the business can fund SG&A and investment from operations as utilization grows, a structurally supportive trait.
Improved LeverageLower leverage reduces financial stress and increases flexibility for capital spending or selective M&A. A more balanced debt-to-equity ratio improves resilience to cash flow variability and supports medium-term strategic investments in clinics and equipment.
Bears Say
Low Net Profit MarginA net margin under 1% means most revenue is absorbed by operating and non-operating costs. This structural weakness limits retained earnings for reinvestment, reduces shock absorption, and makes sustainable shareholder returns dependent on improving cost structure or pricing.
Sharp Free Cash Flow DeclineA near 59% fall in free cash flow constrains the firm’s ability to self-fund equipment replacement and network expansion. Reliance on external financing or higher leverage may follow, increasing liquidity risk and reducing financial flexibility over the medium term.
Weak Return On EquityROE near zero implies capital is not being converted into shareholder returns effectively. Persistently low ROE signals inefficient capital allocation or margin erosion, hindering the company's ability to attract equity investment or justify reinvestment at attractive returns.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$1.91 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$775.53M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 33 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.033 which represents an annual dividend yield of 3.48%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.07 (36.06% Upside)
AU$3.07 (36.06% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$125.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
3.48%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.07
▲(36.06% Upside)
Technical Analysis
Healius Limited
―
BCAL Diagnostics Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Imagion Biosystems Ltd.
―








